Revenue segments as reported by the company.

Water

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Sales and marketing

General and administrative

Research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

IDEXX Laboratories

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water, Livestock, Poultry and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, and is headquartered in Westbrook, ME.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

IDEXX Labs reports robust Q4 performance, eyes international growth

IDEXX Laboratories delivered strong Q4 results with revenue and profit growth, driven by gains in key segments and customer retention.
While facing challenges from inflationary costs and international headwinds, the company aims for continued growth and market differentiation.
Opportunities lie in expanding organic revenue, focusing on international markets, and enhancing customer engagement for future success.

IDEXX reports robust Q1 performance, eyes pet oncology growth

IDEXX Laboratories delivered a strong Q1 performance with revenue and profit growth across segments.
The company's focus on innovation, cloud adoption, and pet oncology diagnostics positions it well for future growth.
Challenges include U.S. clinical vet visit trends and potential market share competition in lab modalities.
Opportunities lie in pet oncology diagnostics, cloud adoption, and international market growth for IDEXX.

IDEXX Laboratories excels in Q2, eyes pet healthcare trends

IDEXX Laboratories demonstrated robust growth in revenues and profitability, driven by strong performance in key segments.
While facing challenges in international markets and margin pressures, the company is poised to capitalize on pet healthcare trends.
Strategic initiatives like product launches and pricing adjustments position IDEXX well for sustained growth and market leadership.

IDEXX Laboratories excels in Q3 earnings amidst capacity challenges

IDEXX Laboratories demonstrated strong financial performance in Q3, driven by revenue growth and operational efficiency.
While facing challenges in clinical visit trends and capacity management, the company's strategic focus on innovation and market expansion positions it well for future growth.
Opportunities lie in addressing capacity constraints, expanding the sales force, and enhancing customer engagement through diagnostics testing.
Overall, IDEXX's commitment to providing integrated solutions and quality services underscores its resilience and potential for sustained success.

IDEXX Labs posts robust Q4 results, eyes growth through innovation

IDEXX Laboratories delivered strong financial performance in Q4 2023 and aims for continued growth in 2024.
The company's focus on innovation, customer feedback, and operational efficiency positions it well for future success.
Challenges include managing expenses, revenue diversification, and maintaining customer value perception.
Opportunities lie in organic revenue growth, margin improvement, and the launch of new diagnostic tests and platforms.

IDEXX Laboratories reports strong Q1 earnings and growth opportunities

IDEXX Laboratories delivered strong financial performance in Q1 2024, driven by solid organic revenue growth and profit gains.
The company remains committed to innovation, customer-centric solutions, and increasing standard of care in Companion Animal Healthcare.
Challenges in clinical visit growth levels and macro impacts on consumer demand are being addressed through operational focus and technology investments.
Opportunities for growth and improvement in software integration and diagnostic utilization dynamics present avenues for future success.

IDEXX Laboratories reports solid Q2 growth amidst sector challenges

IDEXX Laboratories navigated Q2 2024 with solid revenue growth and a focus on innovation and cost management. Despite challenges from sector trends and macroeconomic headwinds, the company remains optimistic about long-term growth prospects. Ongoing launches and a strong balance sheet position IDEXX well for future opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, and is headquartered in Westbrook, ME.

IDEXX (IDXX) registered strong contribution from its CAG business in the third quarter despite pandemic-induced challenges.

IDEXX (IDXX) Earnings Beat Estimates in Q3, Margins Rise

Idexx (IDXX) delivered earnings and revenue surprises of 19.01% and 7.62%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Idexx Laboratories (IDXX) Surpasses Q3 Earnings and Revenue Estimates

Shares of IDEXX Laboratories (NASDAQ:IDXX) were unchanged after the company reported Q3 results.

IDEXX Laboratories: Q3 Earnings Insights

Idexx Laboratories earnings and revenue growth were the best in years for the veterinary products supplier. Shares rose after closing in a buy zone.

Idexx Laboratories Earnings Growth Soars With Stock In Buy Zone

IDEXX's (IDXX) third-quarter top line is likely to have benefited from strength in CAG and LPD businesses.

What's in Store for IDEXX Laboratories (IDXX) in Q3 Earnings?

To get ready for earnings season, look for stocks in or near a potential buy range ahead of their next quarterly report. Idexx Laboratories currently fits that bill.

Idexx Laboratories Stock Forming Handle Ahead Of Earnings Report

LHC Group

ResMed

Here are three growth stocks from the MedTech space that investors can pick ahead of the quarterly releases.

3 MedTech Growth Stocks to Scoop Up Ahead of Q3 Earnings

Does Idexx Laboratories (IDXX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Momentum Investors Will Love Idexx Laboratories (IDXX)

Chewy

Covetrus Inc

Freshpet

PetMed Express

J. M. Smucker

Zoetis

Chewy, Zoetis and FreshPet are just a couple of the names on our list of pet stocks to buy. Let's look at this growing industry more closely.

7 Pet Stocks to Adopt Today 

Idexx (IDXX) possesses solid growth attributes, which could help it handily outperform the market.

Is Idexx (IDXX) a Solid Growth Stock? 3 Reasons to Think " Yes "

Idexx (IDXX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Idexx (IDXX) Hits 52-Week High, Can the Run Continue?

Pool

Veeva Systems

Our indicative theme on Expensive Performers - which includes companies trading at increasingly higher valuation multiples but are executing well, with consistently expanding Operating Margins and Revenues - is up by about 39% year-to-date on an equally weighted basis.This compares to the S&P 500.

Veeva Systems, Pool Corp, IDEXX: Stocks That Look Expensive, But Could Outperform

WESTBROOK, Maine, Oct. 5, 2020 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, has scheduled the release of its 2020 third quarter financial results for Thursday, October 29,...

IDEXX Laboratories to Release 2020 Third Quarter Financial Results

This veterinary services-focused company has characteristics that investors love during recessions, but some metrics that may make you turtle up.

Betting Against IDEXX Labs Because of Coronavirus? You May Be Barking Up the Wrong Tree

Idexx (IDXX) reported earnings 30 days ago. What's next for the stock?

Idexx (IDXX) Up 2.6% Since Last Earnings Report: Can It Continue?

ABIOMED

DexCom

Regeneron Pharmaceuticals

West Pharmaceutical Services

Some of the names on this list may surprise you.

These 5 Stocks Are The Biggest S&P 500 Healthcare Winners of 2020

Bio-Rad Laboratories

Danaher

Hologic

Thermo Fisher Scientific

Vertex Pharmaceuticals

Savvy investors should consider adding these stocks to their portfolio to enhance its performance and diversity.

These 10 Stocks Are the Biggest S&P 500 Healthcare Winners of 2020

Idexx Laboratories saw an improvement in its IBD SmartSelect Composite Rating Monday, from 94 to 96. 
The post Idexx Laboratories Climbs Amid Rising Demand For Pet Products appeared first on Investor's Business Daily.

Idexx Laboratories Climbs Amid Rising Demand For Pet Products

WESTBROOK, Maine, Aug. 13, 2020 /PRNewswire/ -- IDEXX Laboratories, Inc.

IDEXX Laboratories Provides U.S. Companion Animal Market Trends Update

Offers higher image contrast and sharpness, plus reduces radiation dose by 25% or more WESTBROOK, Maine, Aug. 12, 2020 /PRNewswire/ -- IDEXX Laboratories, Inc.

IDEXX expands ImageVue digital imaging portfolio, making enhanced radiation safety and superior diagnostic image quality affordable to more veterinarians

Fast, effortless operation and a small footprint make consistent, accurate in-clinic hematology results accessible to veterinarians worldwide WESTBROOK, Maine, Aug. 12, 2020 /PRNewswire/ -- IDEXX Laboratories, Inc.

IDEXX launches groundbreaking new ProCyte One Hematology Analyzer with dramatically simplified user experience

Idexx (IDXX) Soars to 52-Week High, Time to Cash Out?

IDEXX Laboratories (IDXX) registered strong contribution from its CAG business despite the pandemic-led challenges.

IDEXX (IDXX) Earnings Beat Estimates in Q2, Margins Rise

IDEXX Laboratories, Inc. (IDXX) CEO Jay Mazelsky on Q2 2020 Results - Earnings Call Transcript

Is  (IDXX) Outperforming Other Medical Stocks This Year?

News for IDEXX Laboratories Stock (IDXX)